GeneFerm Biotechnology Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jinde Jin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Jinde Jin

no data

GeneFerm Biotechnology Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021

Recent updates

New minor risk - Profit margin trend

Upcoming dividend of NT$2.00 per share

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: NT$0.20 loss per share (vs NT$0.73 profit in 1Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Full year 2023 earnings released: EPS: NT$3.01 (vs NT$2.26 in FY 2022)

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, Jun 19, 2024

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: NT$1.13 (vs NT$0.72 in 2Q 2022)

Upcoming dividend of NT$1.50 per share at 1.4% yield

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: NT$2.26 (vs NT$1.45 in FY 2021)

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.61 (vs NT$0.45 in 3Q 2021)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings released: EPS: NT$0.50 (vs NT$0.31 in 1Q 2021)

Third quarter 2021 earnings released: EPS NT$0.45 (vs NT$0.15 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of NT$0.083 per share

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.20 loss in 1Q 2020)

GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt

Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)

Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?

Full year 2020 earnings released: EPS NT$0.16 (vs NT$0.99 loss in FY 2019)

GeneFerm Biotechnology Co., Ltd., Annual General Meeting, May 25, 2021

New 90-day high: NT$31.80

Does GeneFerm Biotechnology (GTSM:1796) Have A Healthy Balance Sheet?

New 90-day high: NT$25.50

Third quarter 2020 earnings released: EPS NT$0.14

New 90-day low: NT$20.30

New 90-day low: NT$21.00

New 90-day low - NT$22.35

New 90-day low - NT$22.60

First half earnings released

AMMINISTRATORE DELEGATO

Mandato